Because this unequal benefit might be caused by intrinsic sensitivity or resistance of cancer cells to host immune activity, we assessed these features in each subtype by using gene expression signatures from mouse gastric tumors that are sensitive or resistant to CD8 T cell-dependent anticancer immunity (CD8 T-cell reactive signature [CD8TRS] scores (Supplementary Fig. S13) [36]. This evidence concerns the gene CD8A and gastric neoplasm.